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ABSTRACT
A key task in developing the field of personalized cancer therapy is the 
identification of novel molecular targets that enable treatment of cancers not 
susceptible to other means of specific therapy. The collagen receptor uPARAP/
Endo180 is overexpressed by malignant cells in several non-epithelial cancers, 
notably including sarcomas, glioblastomas and subsets of acute myeloid leukemia. 
In contrast, in healthy adult individuals, expression is restricted to minor subsets of 
mesenchymal cells. Functionally, uPARAP/Endo180 is a rapidly recycling endocytic 
receptor that delivers its cargo directly into the endosomal-lysosomal system, thus 
opening a potential route of entry into receptor-positive cells. This combination 
of specific expression and endocytic function appears well suited for targeting of 
uPARAP/Endo180-positive cancers by antibody-drug conjugate (ADC) mediated drug 
delivery. Therefore, we utilized a specific monoclonal antibody against uPARAP/
Endo180, raised through immunization of a uPARAP/Endo180 knock-out mouse, 
which reacts with both the human and the murine receptor, to construct a uPARAP-
directed ADC. This antibody was coupled to the highly toxic dolastatin derivative, 
monomethyl auristatin E, via a cathepsin-labile valine-citrulline linker. With this ADC, 
we show strong and receptor-dependent cytotoxicity in vitro in uPARAP/Endo180-
positive cancer cell lines of sarcoma, glioblastoma and leukemic origin. Furthermore, 
we demonstrate the potency of the ADC in vivo in a xenograft mouse model with 
human uPARAP/Endo180-positive leukemic cells, obtaining a complete cure of all 
tested mice following intravenous ADC treatment with no sign of adverse effects. Our 
study identifies uPARAP/Endo180 as a promising target for novel therapy against 
several highly malignant cancer types.
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INTRODUCTION
In many cancer types, notably including several 
non-epithelial cancers, there is a strong need for 
novel tumor cell-specific therapy. In these cases, the 
identification and validation of novel cell surface markers 
which may act as tumor-specific targets is a crucial task. 
The urokinase plasminogen activator receptor–associated 
protein (uPARAP, the product of the MRC2 gene, and 
also known as Endo180 or CD280) is a specialized 
component in tissue collagen turnover. This protein, in 
the following designated uPARAP, acts as an endocytic 
receptor internalizing extracellular matrix collagen for 
lysosomal degradation [1–6]. uPARAP has a limited 
distribution in healthy tissues where it is expressed on a 
restricted set of cells of mesenchymal origin, including 
subsets of activated fibroblasts, osteoblasts, and osteocytes 
involved in bone development [2, 7–10]. In contrast, high 
expression levels of uPARAP are found on malignant cells 
of various non-epithelial cancers, including osteosarcomas 
and soft tissue sarcomas [11, 12], glioblastoma multiforme 
(GBM) [13, 14] and subtypes of acute myeloid leukemia 
(AML) (http://servers.binf.ku.dk/bloodspot/, see ref. [15]). 
In the context of molecular cancer targeting, this is an 
interesting expression pattern. There is an urgent need for 
improved means of treatment for all of these cancer types, 
including a demand for novel strategies for specific tumor 
cell-directed therapy [16–18].
One successful strategy for targeting of cancer cells 
through tumor-specific cell surface markers is the use of 
antibody-drug conjugates (ADCs). This strategy combines 
the ability of an antibody to specifically recognize the 
target cell with the effect of an attached drug or cytotoxin, 
thus allowing targeted drug delivery with minimal side-
effects [19–22]. In addition to the strong expression by 
non-epithelial cancers, uPARAP has functional properties 
that might particularly favor an ADC-mediated strategy 
targeting this receptor. Thus, the receptor takes part in 
efficient ligand internalization in a rapid process, where 
the receptor recycles to the cell surface with a frequency 
of several cycles per hour, whereas the initially bound 
cargo is routed to lysosomal degradation [10, 23].
When targeting such cellular receptors, ADC 
constructs rely on mechanisms for intralysosomal 
release of the conjugated cytotoxin from the antibody 
component, before translocation into the cytoplasm can 
be efficiently achieved. Furthermore, the limited number 
of molecular delivery events into each cell dictates the use 
of extremely potent cytotoxins in these ADC constructs 
[19]. One commonly employed mechanism of action 
is based on a highly potent cytotoxin, monomethyl 
auristatin E (MMAE), a synthetic derivative of the tubulin 
inhibitor dolastatin 10a [19, 24, 25], which is coupled to 
an IgG component through a valine-citrulline dipeptide-
containing linker entity [26–28]. With this construct, 
cathepsin-mediated cleavage of the peptide linker in the 
lysosomal compartment liberates the toxin for entry into 
the cytoplasm.
In this work, we have constructed and characterized 
an ADC directed against uPARAP, based on a 
specific monoclonal antibody in combination with the 
aforementioned linker-toxin structure. We show that this 
ADC has strong and target receptor dependent cytotoxicity 
in vitro in a panel of cancer cell lines. Furthermore, we 
demonstrate a high anti-tumor efficiency in vivo in a 
uPARAP-positive tumor model, obtaining a complete cure 
in all mice treated with this ADC.  
RESULTS
Demonstration of uPARAP-expression in cell 
lines from various cancers and target-specific 
endocytosis of antibody 2h9 against uPARAP
Since uPARAP has been reported to be expressed 
by tumor cells in AML, sarcomas and GBM [11–15], we 
first verified that a panel of cultured cell lines derived from 
these diseases express the receptor. The U937 myeloid 
leukemia, the NB-4 acute promyelocytic leukemia, the 
THP-1 monocytic leukemia, the HT1080 fibrosarcoma, 
the GCT (giant cell tumor) fibrous histiocytoma, the RD 
rhabdomyosarcoma, the KNS42 glioblastoma, the HS683 
glioblastoma and U373 MG glioblastoma cell lines 
were all found to express uPARAP by Western blotting 
(Figure 1A). For comparison, we also included a U937 
uPARAP knockout cell line rendered uPARAP negative 
by CRISPR/Cas9 technology (see Methods), as well as 
the non-malignant, embryonic cell line HEK293, which 
previously has been shown to have negligible expression 
of uPARAP [29, 30], and under the same conditions of 
Western blotting showed a signal close to background 
(Figure 1A).
As a candidate antibody to be used in ADC form, we 
focused on a well-defined anti-uPARAP mAb, designated 
2.h.9:F12 (henceforth 2h9). This high-affinity antibody 
was previously raised in the laboratory after immunization 
of a uPARAP knock-out mouse and has been extensively 
characterized, including the demonstration of specific 
reaction with both the human and the murine receptor 
[29, 30].
To show that mAb 2h9 can accumulate specifically 
in uPARAP-positive cells, we labeled the antibody 
with an Alexa Fluor 647 (AF647) fluorophore. For 
fluorescence labeling, we used a coupling method 
based on mild reduction of IgG disulphides followed 
by maleimide conjugation, thus mimicking a preferred 
molecular strategy for preparing an ADC (see Methods). 
As a negative control, we labeled an isotype-matched 
murine mAb, anti-trinitrophenol (aTNP), which has no 
biological recognition partners in human cells [31]. We 
then incubated U937 cells with these fluorescence-labeled 
antibodies, subjected the cells to protease treatment to 
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remove surface-bound fluorescence, and studied the 
cells by confocal microscopy. When incubated with 2h9-
AF647, the cells displayed a pronounced intracellular 
fluorescence with a strong vesicular signal (Figure 1B). 
This staining pattern was equivalent to previously obtained 
results using fluorescence-labeled collagen ligands after 
specific uptake in uPARAP-positive cells, where these 
ligands have been shown to be routed to lysosomes [1–5]. 
No uptake was observed with the negative control, aTNP-
AF647. These data suggested that mAb 2h9 could be 
modified by a reduction/maleimide-dependent conjugation 
procedure and thereby coupled to a low-molecular weight 
hydrophobic moiety, while still being subject to specific 
endocytosis by the target receptor.
Figure 1: Expression of uPARAP by different cancer cell lines and specific cellular uptake of fluorescence-labeled 
mAb 2h9. (A), whole cell lysates of the cancer cell lines U937, THP-1, NB-4, HT1080, GCT, RD, KNS42, HS683 and U373 MG were 
examined for expression of uPARAP by Western blot, together with lysates of uPARAP-deficient U937 cells obtained by CRISPR/Cas9 
technology (“U937 uPARAP k.o.”; see Methods) and non-malignant HEK293 cells. uPARAP was detected using anti-uPARAP mAb 2h9 
as the primary antibody. Bands of apparent Mr 180,000 confirm expression of uPARAP in all of the cancer cell lines except for U937 
uPARAP k.o. Negligible expression of uPARAP is observed in HEK293 cells. An antibody against GAPDH (Mr 37,000) was used as a 
loading control. Asterisk: The THP-1 cell line displayed a reduced GAPDH signal, although identical loading of total protein was used; 
see Methods. (B), demonstration of cellular uptake of AlexaFluor 647-conjugated mAb 2h9. U937 cells were incubated with fluorescently 
labeled uPARAP-directed mAb 2h9 (left) or control mAb aTNP (right), after which the intracellular fluorescence was examined by confocal 
microscopy. Blue: nuclear (Hoechst) stain; green: plasma membrane (anti-hCD45-AlexaFluor 488) stain; red: AlexaFluor 647-labeled 
mAbs. z-stack images verify intracellular, vesicular localization of AlexaFluor 647-labeled antibody only in cells incubated with labeled 
mAb 2h9. Scale bar: 5 µm.
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Preparation and evaluation of a uPARAP-
directed ADC
To create an ADC based on mAb 2h9, we coupled 
the antibody to MMAE via a cathepsin-sensitive linker 
(see Introduction), using partial reduction of IgG 
disulphides and maleimide chemistry, forming an ADC 
designated 2h9-vc-MMAE. An equivalent product was 
created with the control antibody, aTNP. A schematic view 
of the resulting mAb-vc-MMAE ADC structure is shown 
in Figure 2. The molecular drug-to-antibody ratio (DAR) 
was determined using an absorbance-based method (see 
Methods), and it was verified that for both of these mAbs, 
the DAR could be controlled by adjusting the amount of 
maleimide-derivatized linker-toxin reagent present during 
conjugation, with a maximal obtainable DAR of 10 [32] 
(see Methods). This DAR corresponds to labeling of all 
free thiol groups formed from five reduced interchain 
disulphides in a murine IgG1 molecule
Batches of 2h9-vc-MMAE with moderate (~4) or 
high (~10) DAR were analyzed by reducing SDS-PAGE 
and compared with unmodified mAb 2h9. As shown in 
Figure 3A, the ADCs have decreased gel mobility relative 
to the unmodified mAbs and this effect becomes more 
pronounced at a high DAR. The ADC with a moderate 
DAR appeared to be mainly conjugated via heavy chain 
cysteines, evident from the lack of mobility shift of the 
IgG light chain in the DAR~4 batch. In contrast, the ADC 
with a high DAR of 10 appeared to be conjugated via 
both heavy and light chains. To study the sensitivity of the 
conjugate to proteolytic release of the toxin, we incubated 
a sample of 2h9-vc-MMAE (DAR~4) with recombinant 
cathepsin B. This led to a reversion of the electrophoretic 
mobility back to that of unconjugated mAb, indicative 
of valine-citrulline dependent linker cleavage by the 
lysosomal protease (Figure 3B).
To establish that mAb 2h9 retained affinity towards 
uPARAP after the preparation of the ADC, we studied 
the binding of the products to uPARAP in an ELISA 
setup, using dilution series of either unmodified mAbs, 
mAbs subjected to the reduction step of the conjugation 
procedure, or mAb-vc-MMAE ADCs. Reassuringly, both 
the disulphide-reduced mAb 2h9 and the 2h9-vc-MMAE 
ADC displayed a concentration dependent binding 
nearly identical with that of the unmodified mAb (Figure 
3C). Since the binding curves obtained include the sub-
nanomolar concentration range, this result points to an 
unchanged or negligible loss of affinity towards uPARAP, 
and confirms that mAb 2h9 tolerates the conjugation 
procedure with the linker-toxin construct well.
uPARAP-dependent cytotoxicity of ADC 2h9-vc-
MMAE in vitro
In order to evaluate the cytotoxic potential 
of uPARAP-directed ADC 2h9-vc-MMAE, cells 
demonstrated above to be positive or negative for uPARAP 
expression were incubated with a dilution series of either 
Figure 2: Schematic view of the uPARAP-directed ADC showing the structural constituents of a mAb-vc-MMAE 
ADC. Attachment group: A thiol-directed maleimidocaproyl group. Linker region: valine-citrulline-p-aminobenzoyloxycarbonyl, “vc”. 
Cytotoxic component: monomethyl auristatin E (MMAE), a potent tubulin inhibitor. The DAR is readily adjustable (see Methods), and a 
maximal DAR of 10 can be obtained with a murine IgG1 using the employed protocol.
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Figure 3: Molecular characterization of ADC products. (A), reducing SDS-PAGE of unmodified mAb 2h9, ADC 2h9-vc-MMAE 
(DAR~4) and ADC 2h9-vc-MMAE (DAR~10). The electrophoretic gel mobilities of the ADC species are reduced with increasing DAR. 
2h9-vc-MMAE (DAR~4) is conjugated mainly via the heavy chains (“HC”), whereas 2h9-vc-MMAE (DAR~10) is conjugated via both the 
heavy and the light chains (“LC”). (B), Reducing SDS-PAGE of mAb 2h9 and ADC 2h9-vc-MMAE (DAR~4) incubated in the absence or 
presence of recombinant human (rh) cathepsin B. rhCathepsin B reverts the mobility of 2h9-vc-MMAE back to that of mAb 2h9, indicative 
of linker cleavage and drug release. (C) ELISA analysis of unmodified mAbs 2h9 or aTNP (white), reduced mAbs (grey), or mAb-vc-
MMAE (DAR~4) ADCs (black), in binding to immobilized uPARAP. 2h9-vc-MMAE displays only negligible loss of affinity towards 
uPARAP following reduction as well as conjugation.
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2h9-vc-MMAE or control ADC aTNP-vc-MMAE for 
72 hours, and thereafter analyzed for cytotoxicity of 
the ADCs by a cell viability assay (Figure 4). All of the 
uPARAP-positive cell lines showed specific sensitivity 
towards 2h9-vc-MMAE, with leukemia cell lines U937 
and NB-4 displaying the most pronounced loss of 
viability. A smaller, nonspecific effect of the negative 
control conjugate was noted at the highest concentrations 
(> 2.5 µg/mL mAb component) in some cell lines, but 
importantly still leaving a large therapeutic window of 
specificity for 2h9-vc-MMAE. HEK293 cells, as well as 
the aforementioned U937 uPARAP knock-out clone (see 
Figure 1A and Methods), were irresponsive towards 2h9-
vc-MMAE, thus demonstrating that the cytotoxic effect of 
this ADC is target receptor specific.
To further substantiate the specificity of the cytotoxic 
effect, a competition assay was performed. U937 cells were 
incubated with 2h9-vc-MMAE at 1 µg/mL mAb component 
in the presence of increasing amounts of potential 
competitors. The latter reagents included unmodified mAb 
2h9, a mAb designated 5f4 which recognizes a different 
epitope on uPARAP [30], and the negative control mAb, 
aTNP. The uncoupled mAb 2h9 had pronounced efficacy in 
rescuing cells from 2h9-vc-MMAE mediated cytotoxicity, 
whereas no effect was found with the other antibodies 
(Figure 5A). The mAb 5f4 has been studied extensively 
previously, and has been shown to deplete uPARAP from 
the cell surface upon long-term incubation, due to failure 
of receptor recycling [33]. Therefore, we also studied 
the effect of this antibody in a preincubation experiment, 
where mAb 5f4 was added before the addition of 2h9-vc-
MMAE. Indeed, preincubating U937 cells with mAb 5f4 
for 3 hours resulted in a ~10 fold decrease in the toxicity of 
subsequently added 2h9-vc-MMAE (Figure 5B).
Next, to study whether the cytotoxicity of 2h9-vc-
MMAE was dependent on lysosomal linker cleavage, we 
tested the effect of E-64D, an inhibitor capable of entering 
the lysosomal compartment and blocking the activity of 
several lysosomal cysteine proteases including cathepsin 
B [34]. U937 cells were preincubated with E-64D, after 
which the cellular sensitivity was determined by adding a 
dilution series of the ADCs. As shown in Figure 5C, this 
pretreatment abrogated the cytotoxic effect of 2h9-vc-
MMAE.
Figure 4: Effect of uPARAP-directed ADC 2h9-vc-MMAE on uPARAP-positive cancer cells in vitro. MTS-based cell 
viability assays. Curves display the concentration dependent reduction in cell population viability obtained with uPARAP-directed ADC 
2h9-vc-MMAE (red) versus control ADC aTNP-vc-MMAE (grey) in uPARAP-positive U937, THP-1, NB-4, HT1080, GCT, RD, KNS42, 
HS683 and U373 MG cells, as well as in U937 uPARAP knockout cells and HEK293 cells. Viability is shown as percentage of viable cells, 
normalized to an untreated control population.
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Altogether, these experiments showed that the 
cytotoxic effect of 2h9-vc-MMAE is dependent on the 
interaction between the targeting antibody and the target 
receptor, as well as lysosomal cleavage of the valine-
citrulline-containing ADC linker.
MMAE is an extremely potent inhibitor of tubulin 
polymerization and is highly cytotoxic, being directed 
particularly against actively dividing cells. However, the 
compound may not always mediate cell killing directly, 
as affected cells may instead be arrested in the G2/M cell 
cycle phase due to failure of mitotic spindle assembly 
[19]. Therefore, in order to investigate the mechanism 
underlying the observed reduction in overall viability of 
the cells, we determined the cell cycle distribution of the 
sensitive cell lines shown above, following incubation 
with 2h9-vc-MMAE at a concentration resulting in a 50% 
reduction in viability, as demonstrated in Figure 4. In these 
experiments, shown in Table 1, all leukemia cell lines 
(U937, NB-4 and THP-1) displayed a clear propensity 
towards apoptosis over growth arrest upon exposure to 
2h9-vc-MMAE, evident from the increase in percentage 
of cells mainly in the sub-G1 cell cycle phase. Similar data 
was found for the sarcoma cell line HT1080, whereas the 
GCT cell line showed an increase mainly in the fraction 
of cells in the G2/M phase. The RD sarcoma cell line, as 
well as GBM cell lines KNS42, HS683 and U373 MG, 
showed a mixed response, with increased fractions of cells 
both in the sub-G1 phase and the G2/M phase, indicative 
of effects resulting in apoptosis as well as growth arrest. 
Thus, these data demonstrate composite mechanisms of 
inhibition of cancer cell growth in the cell lines tested. 
This opens the possibility that both a direct cytotoxicity 
and a non-lethal inhibition of cell division by the cytotoxin 
MMAE may contribute to counteracting tumor growth in 
certain cancer forms.
Eradication of uPARAP-positive tumors in mice
The sensitivity of the U937 cell line towards ADC 
2h9-vc-MMAE in vitro appeared highly promising for 
in vivo investigation, since AML models in mice based 
on this cell line are well established [35–38], and since 
uPARAP is strongly upregulated in certain AML subsets 
in humans [15]. In contrast, normal leukocytes in the 
circulation are generally uPARAP-negative [6]. Therefore, 
in order to investigate a potential anti-tumor effect of 2h9-
vc-MMAE in vivo, we next set up a xenograft model with 
U937 cells, using subcutaneous inoculation of cells in 
CB17 SCID mice [35, 36].
In this system, the growth of the resulting tumors 
can be easily evaluated by palpation. In the absence of 
treatment, subcutaneous injection with U937 cells led 
to the establishment of local tumors within approx. two 
weeks, with a doubling time of tumor volume of 3 to 4 days 
(see Methods; data not shown). Immunohistochemical 
staining of these tumors revealed a positive staining 
for uPARAP in tumor cells. uPARAP staining was 
predominantly observed in the outermost part of the tumor 
Figure 5: Specificity of the cytotoxic effect of 2h9-vc-MMAE, and importance of cathepsin-mediated linker cleavage. 
MTS-based cell viability assays were performed as in Figure 4, except that additional reagents were added as indicated. (A), receptor 
competition assay with unmodified mAbs. Viability curves obtained upon incubation of U937 cells with 1 µg/mL of 2h9-vc-MMAE 
in the simultaneous presence of increasing amounts of potential competitor mAbs, using either mAb 2h9 (red), mAb aTNP (grey) or 
a different uPARAP-directed mAb (5f4; blue). Only mAb 2h9 rescues the cells from 2h9-vc-MMAE mediated toxicity. (B), effect of 
target receptor depletion on ADC toxicity. Viability curves of U937 cells obtained with a concentration series of 2h9-vc-MMAE, either 
without pretreatment of cells (red), following a 3 hour preincubation with uPARAP-depleting mAb 5f4 (green; see text), or obtained with a 
concentration series of ADC aTNP-vc-MMAE (grey). Preincubation with mAb 5f4 decreases the impact of 2h9-vc-MMAE on cell viability 
approximately 10-fold. (C), inhibition of lysosomal ADC linker cleavage and drug release. Viability curves of U937 cells obtained in the 
presence of ADCs 2h9-vc-MMAE (red), aTNP-vc-MMAE (grey), or 2h9-vc-MMAE following preincubation of cells with 20 µM of an 
inhibitor of lysosomal proteases (E-64D, purple). Incubation in the presence of E-64D abrogates the toxic effect of 2h9-vc-MMAE.
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tissue (Figure 6A), which was also the case after positive 
control staining for human CD45 (Figure 6B), confirming 
the human origin of the stained cells. Thus, tumor cells 
retained uPARAP expression when growing in vivo. Ki-
67 staining of the tumor tissue revealed a high proportion 
of actively proliferating cells (Figure 6C), as expected 
considering the rapid tumor growth observed by palpation. 
Staining for apoptosis showed very little positive signal in 
the tumor tissue, demonstrating a very low abundance of 
apoptotic cells (Figure 6D). Evaluation of H&E stained 
tumor tissue indicated that tumors are densely packed with 
cancer cells (small round cells), with a relatively small 
contribution of stromal cells with a typical elongated 
fibroblast morphology (black arrows). In addition, staining 
confirmed intact nuclei of the far majority of cells present, 
with no obvious signs of necrosis (Figure 6E)
To initially test animal tolerance towards the ADCs 
in the absence of tumors, a subcutaneous injection of a 
single high dose (15 mg/kg) of either 2h9-vc-MMAE 
(N=2) or aTNP-vc-MMAE (N=2) at a moderate DAR of 
~4 was performed. Animals were then closely monitored 
for signs of distress or aberrant behavior and weighed 
daily for a 7-day period. No weight loss or signs of 
abnormal behavior was observed, thus demonstrating 
gross tolerance towards these ADCs.
We then tested the effect of local ADC treatment 
in tumor-bearing mice. Randomized groups of mice were 
treated with either uPARAP-directed ADC 2h9-vc-MMAE, 
control ADC aTNP-vc-MMAE, unmodified mAb 2h9, or 
PBS vehicle control, respectively. Treatment was initiated 
after the establishment of palpable tumors of 50-100 mm3, 
with each mouse receiving 4 subcutaneous doses of 3 mg/kg 
mAb component in the tumor area, with four-day intervals. 
Tumors in mice receiving aTNP-vc-MMAE or unmodified 
mAb 2h9 showed unaffected tumor growth relative to the 
PBS vehicle control group, and all mice in these groups 
reached a point of sacrifice due to tumor size after 9-12 
days of treatment. In contrast, the group of mice treated 
with 2h9-vc-MMAE showed a strong reduction in tumor 
growth (Figure 7A). Indeed, after completion of treatment, 
9 out of 10 mice in this group had reached a point where no 
palpable tumors could be detected. These mice were then 
followed for an observation period of 3 months without 
further treatment. As shown in the Kaplan-Meyer plot 
(Figure 7B), a full cure was obtained in 5 of these animals, 
with no signs of relapse throughout this observation period. 
Table 1: Cell cycle phase distribution of uPARAP-positive cell lines after treatment with 2h9-vc-MMAE
Cell line Sub-G1 G1 S G2/M
U937 Untreated 7,2 ± 0,3 62 ± 0,4 24,3 ± 0,3 6,3 ± 0,3
2h9-vc-MMAE 30,0 ± 5,2 * 31,2 ± 1,6 27,6 ± 3,7 10,8 ± 0,9 *
NB4 Untreated 6,2 ± 0,5 49,6 ± 1,1 31,9 ± 0,9 12,2 ± 0,6
2h9-vc-MMAE 47,4 ± 1,1 * 15,4 ± 0,0 27,2 ± 1,6 9,4 ± 0,4
THP-1 Untreated 3,0 ± 0,2 63,7 ± 0,4 19,3 ± 0,3 14,3 ± 0,9
2h9-vc-MMAE 22,0 ± 13,2 * 36,9 ± 17,8 26,3 ± 4,6 14,2 ± 0,7
HT1080 Untreated 1,6 ± 0,7 68,7 ± 0,7 9,9 ± 0,6 19,8 ± 1,2
2h9-vc-MMAE 22,3 ± 2,0 * 41,2 ± 0,9 17,9 ± 0,6 18,5 ± 1,0
GCT Untreated 8,1 ± 0,3 70,5 ± 1,0 10,6 ± 1,1 10,6 ± 0,9
2h9-vc-MMAE 9,9 ± 1,0 57,6 ± 0,7 16,0 ± 1,1 16,4 ± 1,1 *
RD Untreated 2,9 ± 0,4 57,8 ± 1,7 21,4 ± 2,0 17,9 ± 0,7
2h9-vc-MMAE 9,2 ± 0,9 * 42,4 ± 2,1 22,7 ± 1,8 25,6 ± 0,7 *
KNS42 Untreated 4,8 ± 0,6 68,9 ± 0,4 14,1 ± 1,2 11,0 ± 1,8
2h9-vc-MMAE 35,9 ± 3,0 * 23,3 ± 0,3 15,2 ± 1,4 23,2 ± 1,8 *
HS683 Untreated 6,5 ± 1,7 59,0 ± 0,6 12,5 ± 2,6 22,0 ± 1,9
2h9-vc-MMAE 17,8 ± 1,9 * 31,7 ± 0,1 19,7 ± 1,2 30,8 ± 0,9 *
U373 Untreated 4,2 ± 1,0 62,6 ± 1,6 16,3 ± 1,3 15,7 ± 1,7
2h9-vc-MMAE 29,5 ± 1,5 * 23,4 ± 1,3 19,6 ± 1,0 25,6 ± 0,8 *
The cell cycle phase distribution of cancer cell lines, comparing untreated cells to cells following incubation with 2h9-vc-
MMAE over three days. The ADC was added at a final concentration resulting in 50% overall cell viability, as previously 
determined by viability assay (see Figure 4). Bold numbers marked with an asterisk indicate a significant shift in the 
percentage of cells in a given cell cycle phase (t-test: p<0.01).
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Notably, these surviving mice did not show any signs of 
detrimental side effects, referring to the criteria above and 
general observation of animal behavior. In contrast, 4 of 
the above 9 mice did show a rapid relapse of tumor growth 
after termination of treatment. Western blot analysis of 
tumor tissue revealed that tumors harvested from mice with 
relapse, as well as tumors from all other treatment groups, 
were still positive for uPARAP at the point of sacrifice 
Figure 6: Histology of untreated U937 tumors. Histological examination of untreated U937 tumor specimens after inoculation and 
growth in CB17 SCID mice. (A and B), immunohistochemical localization of uPARAP (A) and human CD45 (B) reveals positive staining 
of tumor cells (reddish brown), shown at low and high magnification(scale bars 100 µm and 50 µm, respectively). (C), Ki-67 staining of 
tumor tissue, revealing a high proportion of actively proliferating tumor cells (black arrows). Scale bar: 25 µm. (D), Staining of tumor tissue 
for apoptosis, demonstrating a very low abundance of apoptotic cells (black arrows). Scale bar: 50 µm. (E), H&E staining of tumor tissue 
revealed a uniform and dense distribution of tumor cells throughout the entire tumor with relatively few cells with stromal morphology 
(black arrows). Scale bar: 50 µm.
Figure 7: Treatment of tumors in vivo: Subcutaneous U937 tumors subjected to local administration of 2h9-vc-MMAE. 
Mice were inoculated with U937 cells by subcutaneous injection. Upon the appearance of palpable tumors, local treatment with the 
indicated reagents was initiated by subcutaneous injection at the tumor site (set as time point day 0). Treatments were given as doses of 3 
mg/kg mAb component at day 0, 4, 8 and 12 (black triangles). Treatment groups received 2h9-vc-MMAE (N=10, red), aTNP-vc-MMAE 
(N=9, green), unconjugated mAb 2h9 (N=5, blue) or PBS (N=5, purple). (A), comparison of the average tumor volume across treatment 
groups, shown until treatment day 28. (B), Kaplan-Meier plot showing survival of the treatment groups shown in panel A, during an 
observation period of three months after finishing treatment.
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(Supplementary Figure 1). This result pointed to incomplete 
targeting and elimination of uPARAP-positive tumor cells 
as being the main reason for the different outcomes for mice 
in the 2h9-vc-MMAE-treated group, rather than loss of the 
target receptor during treatment.
Finally, we tested the effect of systemic 
treatment with 2h9-vc-MMAE. Mice were inoculated 
with subcutaneous U937 tumors as above, and after 
establishment of palpable tumors of 50-100 mm3, ADCs 
were administered intravenously, with a total of 3 
injections of 5 mg/kg mAb component in a tail vein with 
four-day intervals. An additional treatment group was 
included for comparison, receiving local subcutaneous 
treatment with 2h9-vc-MMAE as above, but with the 
same dose and treatment schedule as the groups receiving 
intravenous treatment. Remarkably, intravenous treatment 
with 2h9-vc-MMAE resulted in a complete cure of all 
mice, with no recurrent tumor growth over a 3 month 
observation period (Figure 8A). The same outcome was 
obtained after local subcutaneous treatment with this 
slightly elevated dose of the ADC (Figure 8B).
Survival of the intravenously treated mice is shown 
in a Kaplan Meier plot (Figure 8C). Although tumors were 
not completely inert to intravenous treatment with control 
ADC aTNP-vc-MMAE (Figure 8A and 8C), the effect 
noted in this group was much less pronounced than that 
obtained with 2h9-vc-MMAE, and most likely was the 
result of an enhanced permeability and retention (EPR) 
effect (see Discussion).
The group of mice treated systemically with 2h9-
vc-MMAE was followed throughout the treatment and 
a 3 month observation period. The mice showed no 
weight loss during the treatment period (Figure 8D), and 
observations revealed no negative side effects in terms of 
aberrant animal behavior.
A separate group of U937 tumor-bearing mice was 
then treated with a single intravenous injection of 2h9-vc-
MMAE at 5 mg/kg, and upon tumor shrinkage confirmed 
by palpation, these tumors were resected and subjected 
to histological analysis. Staining of the tumor tissue for 
apoptotic cells revealed an extensive positive staining 
across the entire tumor, indicative of efficient targeting 
of tumor cells by 2h9-vc-MMAE, with the surrounding 
stromal tissue being largely negative for apoptosis 
(Figure 8E). This pattern of extensive cell death in the 
tumor tissue, with cells of the tumor stroma remaining 
unaffected, was confirmed by H&E staining (Figure 8F).
To further study potential side effects, we examined 
the histology of mouse livers during ADC treatment for 
any signs of acute, non-specific hepatotoxicity. H&E 
staining of liver sections of treated mice, obtained at 
the same time point as above where tumor regression 
was evident, revealed no histological abnormalities [39, 
40], and no differences between untreated and treated 
livers could be noted (compare Figure 8G and 8H). 
Furthermore, to look into the fate of healthy cells that 
do express uPARAP, we focused on bone lining cells 
that are well documented to express the receptor [41]. 
At the time of tumor regression, bones of treated mice 
were indistinguishable from those of untreated mice, and 
bone lining cells were in both cases positive for uPARAP 
expression (compare Figure 8I and 8J).
Taken together, these results demonstrate highly 
efficient tumor penetration and targeting of tumor cells 
by ADC 2h9-vc-MMAE. Additionally, uPARAP-positive 
host cells appeared to be unaffected, adding to the tumor 
specificity of this ADC.
DISCUSSION
In this work, we have identified the collagen 
receptor uPARAP as a novel and highly promising target 
for specific drug delivery to different types of non-
epithelial cancers. Cancer cells positive for this receptor 
are dominant in sarcomas [11, 12], GBM [13, 14] and 
subtypes of AML [15], and uPARAP positive cell lines 
derived from these cancers were demonstrated to be 
sensitive in vitro to our uPARAP-directed ADC in a target 
receptor specific manner (Figure 4, Figure 5 and Table 1). 
Treatment experiments in vivo with transplanted U937 
cells in mice led to complete eradication of established 
tumors (Figure 8).
The use of ADCs for targeted drug delivery is a 
rapidly growing approach, with the number of new clinical 
trials on ADC drugs having increased steadily for the 
last decade. As of late 2016, almost 100 different ADC 
species had undergone clinical testing in various forms of 
cancer, with about 60 ADCs in active testing, and more 
than 100 preclinical ADCs underway [42]. The process 
of developing these potential drugs has led to substantial 
understanding of factors critical for a successful ADC 
strategy. Notably, this includes the utilization of extremely 
cytotoxic agents which, in their free form, would be much 
too toxic to be safely used for cancer therapy, as well as 
the introduction of molecular properties that make the 
ADCs non-toxic before specific release of the conjugated 
toxin inside the target cell [19, 22].
The linker-toxin entity used in our work, vc-MMAE, 
was originally developed in pioneering studies to create the 
ADC Brentuximab Vedotin (Adcetris®), directed against 
CD30-positive cancers [26, 27, 43, 44]], and since then, vc-
MMAE has been widely used in ADC development [21, 
42]. Although the functional properties of a combination 
of a certain IgG molecule and any linker-toxin construct is 
unpredictable, we showed that the mAb 2h9 directed against 
uPARAP could be efficiently coupled to vc-MMAE using 
a reduction/maleimide conjugation method, with negligible 
loss of affinity towards the target receptor. The resulting 
uPARAP-directed ADC was proven to be efficacious 
against a panel of uPARAP-positive cancer cell lines with 
negative control cells being unaffected, demonstrating 
uPARAP-dependent cytotoxicity.
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Figure 8: Treatment of tumors in vivo: Eradication of subcutaneous U937 tumors by intravenous administration 
of 2h9-vc-MMAE. The experiment was performed as described for Figure 7, except that mice received three doses of 5 mg/kg mAb 
component by intravenous (A, C) or subcutaneous (B) injections at day 0, 4, and 8 (black triangles). (A) comparison of the average tumor 
volume for systemically treated mice across treatment groups. Curves display groups of mice receiving intravenous injections of 2h9-vc-
MMAE (N=10, red), aTNP-vc-MMAE (N=10, green), unconjugated mAb 2h9 (N=5, blue) or PBS (N=5, purple). Mice were followed 
for an observation period of three months after finishing treatment. The curve for the aTNP-vc-MMAE treatment group is discontinued 
from day 28, when only one surviving mouse remained; this one mouse had no detectable tumor. (B) average tumor volume for a group 
of mice that received three subcutaneous injections of 2h9-vc-MMAE at 5 mg/kg mAb component at the tumor site (N=5, red). (C) 
Kaplan-Meier plot showing survival percentages of the treatment groups shown in panel A. (D), individual weight curves of the 10 mice 
receiving intravenous injections of 2h9-vc-MMAE in panel A, demonstrating stable weight of all treated mice during the treatment period. 
(E-J), histological examination of tumor and mouse tissue during the process of tumor regression upon 2h9-vc-MMAE treatment. Mice 
were inoculated with U937 cells as above. After establishment of tumors, mice received a single dose of 2h9-vc-MMAE (5 mg/kg mAb 
component) by intravenous injection. After four days, tumor shrinkage was confirmed by palpation, mice were sacrificed and histological 
examination was performed. E, staining of tumor tissue for apoptosis revealing extensive apoptosis of tumor cells upon treatment with 2h9-
vc-MMAE, whereas stromal cells are unaffected. “T”: tumor cells, “S”: stromal cells, dotted line: tumor front, scale bar: 50 µm. F, H&E 
staining of tumor tissue, revealing extensive tumor cell death (little or no nuclear staining), with surrounding viable stromal cells. Symbols 
and scale bar as in E. G and H, liver sections from untreated (G) or 2h9-vc-MMAE-treated mice (H), revealing no difference after H&E 
staining. Scale bars: 100 µm. I and J, bone sections (femur) from untreated (I) or 2h9-vc-MMAE-treated mice (J) were immunostained 
for uPARAP. Sections appeared identical, with prominent uPARAP staining in bone lining cells (reddish-brown, black arrows) of both 
untreated and treated mice, suggesting minimal target-specific killing of endogenous uARAP-positive cells. Scale bars: 100 µm.
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The current combination of molecular target and use 
of an ADC strategy has several advantageous properties. 
In addition to the unique cellular expression pattern, the 
targeted molecule uPARAP is an efficiently recycling 
endocytic component, belonging to the clathrin-associated 
group of constitutive internalization receptors with direct 
lysosomal delivery of cargo [1–6]. These endocytic 
properties are rarely found among existing ADC targets 
in clinical testing [21, 42] and may likely contribute to 
a high efficiency of ADC internalization, which in turn 
may favor efficacy of treatment with this type of ADC. In 
contrast, ADC targeting of cell surface proteins which are 
not bona fide internalization receptors has often required 
the development of specialized antibodies, which actively 
induce the internalization of these targets [45], or even 
more complex bispecific antibody formats, in order to 
obtain efficient ADC internalization [46].
While our ADC was highly specific in killing and/
or inducing growth arrest in uPARAP-positive tumor 
cells in vitro, there appeared to be no simple correlation 
between the degree of sensitivity and the apparent levels 
of uPARAP expression in the target cells (compare Figure 
1A, Figure 4 and Table 1). A similar situation has often 
been reported for other ADCs in pre-clinical studies, 
where ADC cytotoxicity does not necessarily reflect the 
target receptor expression level in a simple linear manner 
[26, 47, 48]. Although a high expression level of any target 
receptor would be considered beneficial in regards to ADC 
efficacy against a certain type of cancer cell, there is a 
general consensus that several additional factors influence 
the overall sensitivity towards a given ADC species [19–
22]. Notably, these factors include a variable sensitivity 
towards the cytotoxin component of the ADC, which in 
turn may be influenced by the expression of multidrug 
resistance transporters [49] and, in the case of tubulin 
inhibitors such as MMAE, the propensity to cell division. 
Other factors may include the overall internalization and 
routing rates of ADCs [50, 51], as well as the cellular 
capacity for linker cleavage. It is not unlikely that all of 
these factors contribute to the variations in sensitivity 
observed in our panel of cancer cell lines (Figure 4 
and Table 1). In particular, we demonstrated that ADC 
efficiency in highly sensitive cells such as U937 cells is 
completely dependent on lysosomal linker cleavage, since 
uPARAP-dependent cytotoxicity was abrogated after 
inhibition of lysosomal proteases with E-64D (Figure 5C).
The mAb 2h9 was obtained after immunization of 
a uPARAP gene-deficient mouse and is reactive with an 
epitope shared between human and murine uPARAP [29, 
30]. This leads to a great advantage when using xenograft 
tumor models in mice, since treatment with a 2h9-based 
ADC will not only reveal a successful targeting of human 
tumor cells, but also any potential target-dependent 
toxicity in the host organism. We found ADC 2h9-vc-
MMAE to be well tolerated at high doses in mice, and no 
side-effects were observed in the three month observation 
period following successful treatment. This is not 
unexpected in the light of the known expression pattern of 
this receptor. Both in humans and mice, although uPARAP 
is found in a variety of organs, the expression is restricted 
to a limited set of activated, mesenchymal cell types in 
the healthy adult organism, typically in connection with 
tissue remodeling (reviewed in [6]). Although a detailed 
toxicology study was not performed in this work, our 
results suggest that healthy uPARAP-positive host cells are 
not particularly sensitive to 2h9-vc-MMAE. A prominent 
example of healthy, uPARAP-expressing cells is bone 
lining cells which take part in bone collagen metabolism 
[41]. However, these cells were intact and retained 
uPARAP expression during ADC treatment (Figure 8I and 
8J), even though at the same time point, tumor regression 
and extensive apoptosis of tumor cells was evident (Figure 
8E and 8F). Most likely, the resistance of bone lining cells 
towards 2h9-vc-MMAE is due to factors such as a low 
mitotic activity discussed above, which further contribute 
to narrow the specificity of treatment to uPARAP-
expressing tumor cells. Regarding generalized (non-target 
related) activity of ADCs, this is often revealed in the 
form of hepatotoxicity, with necrosis and inflammation 
being evident upon simple inspection of liver sections as 
found in mouse studies [39, 40]. However, no sign of liver 
damage was observed upon treatment with 2h9-vc-MMAE 
(Figure 8G and 8H).
In our xenograft tumor model with U937 cells in 
CB17 SCID mice, intravenous administration of 2h9-
vc-MMAE led to a 100% cure rate of the treated mice. 
By far the major element in this effect was a uPARAP-
dependent cytotoxicity, as evident from a comparison of 
the four treatment groups (Figure 8A and 8C). Although 
the detailed mechanism of cell death was not pursued in 
vivo, immunohistochemical studies performed on 2h9-
vc-MMAE-treated tumors during the regression phase 
showed that a single injection of 2h9-vc-MMAE led to 
widespread and specific death of cancer cells, while 
surrounding stromal cells remained unaffected by ADC 
treatment (Figure 8E and 8F).
In addition to uPARAP-specific eradication of 
tumors, a slight unspecific effect was also noted in vivo, 
with the non-targeted control ADC, aTNP-vc-MMAE, 
displaying a much lower but still measureable effect on 
tumor growth (Figure 8A and 8C). Similar observations 
have been done in other ADC studies, including 
investigations that employ the vc-MMAE linker-toxin 
construct with different targeting antibodies [27, 48, 
52–55]. The unspecific contribution to such an anti-
tumor effect is usually ascribed to an EPR phenomenon, 
resulting in accumulation of macromolecular drugs in the 
tumor microenvironment due to leaky vasculature and 
a lack of lymphatic clearance, as well as extracellular 
cleavage and/or degradation of ADCs in the intratumoral 
area [56, 57]. To this end, additional studies have shown 
that non-internalizing ADCs, based on more labile linker 
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chemistries, can even in some cases contribute to treating 
solid tumors by passive diffusion of released cytotoxins 
[58, 59].
In this work we utilized a well described AML 
xenograft model to show the efficiency of our uPARAP-
directed ADC in vivo. However, the potential therapeutic 
utilization may cover several additional types of 
cancers. The expression patterns described above would 
point directly to sarcomas and glioblastoma as likely 
indications, i.e. very severe diseases for which only few 
options for targeted therapy exist [16–18]. Indeed, we 
have recently studied the expression and importance of 
uPARAP particularly in osteosarcoma, where just the 
functional inhibition of this receptor leads to a pronounced 
counteraction of tumor-mediated bone degeneration in a 
mouse model [11]. In connection with treatment of this 
disease, it is particularly promising that we found healthy, 
uPARAP-positive bone lining cells to be tolerant to 
systemic ADC treatment in the current study.
In addition to these cancer forms, uPARAP displays 
a strong upregulation in the stromal compartment of 
several cancers of epithelial origin, including breast [60–
62], head and neck [30] and prostate cancer, where even a 
mixed tumor-stroma expression has been reported for the 
latter [63, 64]. Along with an increasing understanding of 
the functional importance of the tumor microenvironment, 
an increasing interest is now devoted to therapeutic 
targeting of stromal cells in cancer [65–68], as well as 
bystander effects utilizing stromal liberation of the toxin 
components of ADCs. In this connection, our uPARAP-
directed ADC may also be a highly efficient reagent, due 
to the cell permeability of the liberated MMAE toxin.
In all potential indications for treatment with a 
uPARAP-directed ADC, the complete target specificity 
is a great advantage, not only for reducing side effects 
but also for the option of selecting individual patients 
for treatment. Most of the diseases discussed above are 
highly heterogeneous in their protein expression pattern 
and therefore, an immunohistochemical examination 
of primary tumor material should strongly aid the 
identification of patients with a dominant expression of 
the target protein.
The linker-toxin combination employed in this 
study, vc-MMAE, is currently the most widely employed 
construct in the ADC field [22, 42]. However, novel ADC 
functionalities are continuously being developed. These 
include improved and site-directed attachment chemistries, 
improved linkers, and especially in current years more 
potent cytotoxins [19-21, 25, 69]. These innovations all 
contribute to a continuously increasing perfection of ADC 
synthesis and function, while studies such as the one 
presented here should potentially contribute to expanding 
the scope of ADC utilization in preclinical as well as 
clinical settings via the identification of novel targets.
We hope that the novel findings presented in this 
work will pave the way for a further development of 
uPARAP-directed ADCs, and ultimately lead to actual 
cancer therapy based on the concepts introduced in 
this study. This may be an important contribution to 
combatting cancer types with an urgent need for novel 
means of treatment.
MATERIALS AND METHODS
Antibodies and cell lines
uPARAP-directed mAbs 2h9 and 5f4 of isotype 
IgG1k, as well as the isotype-matched control mAb 
directed against trinitrophenol, aTNP, were produced at 
the laboratory using hybridoma cell cultures as described 
previously [30, 31, 70, 71]].
U937 (ATCC# CRL 1593.2), THP-1 (ATCC# TIB-
202), HT1080 (ATCC# CCL 121), GCT (ATCC# TIB-
223), RD (ATCC# CCL-136), HS683 (ATCC# HTB-138), 
U373 MG (ATCC# HTB-17) and HEK293 (ATCC# CRL-
1573) cells were all obtained from ATCC. KNS42 cells 
were kindly provided by Drs. Lara Perryman and Janine 
Erler, Biotech Research and Innovation Centre (BRIC), 
University of Copenhagen. NB-4 cells were kindly 
provided by Dr. Kim Theilgaard-Mönch, The Finsen 
Laboratory, Copenhagen University Hospital.
A U937 cell line, deficient for uPARAP expression for 
use as a negative control, was prepared by CRISPR/Cas9 
technology using previously published detailed protocols 
[72]. In brief, a human uPARAP sgRNA1 (5′-GCCGAA
ACCGGCTATTCAACCTGG-3′) was designed to target 
exon 2 of the uPARAP gene, corresponding to the Cysteine-
rich domain in the N-terminal part of the protein. After 
sgRNA1 cloning into the plasmid pSpCas9(BB)-2A-GFP, 
the resulting plasmid was used for transfection of U937 
cells using Lipofectamine 3000. Positively transfected cells 
were selected using FACS enrichment of GFP expressing 
cells followed by single cell sorting into 96-well plates [73]. 
Single clones were screened for the absence of uPARAP 
expression by flow cytometry in 96-well format using anti-
uPARAP mAb 5f4 for staining, and clones with a negative 
staining signal in comparison to wild-type control cells 
were further propagated in cell culture. uPARAP deficiency 
was further confirmed by Western blotting using anti-
uPARAP mAb 2h9. Genomic DNA of selected clones was 
purified and subjected to PCR amplification of the region 
surrounding the expected Cas9 target site by use of forward 
(5′-AACGTATGAGTGACGGCTCA-3′) and reverse 
(5′-CTCCTCGCTGCCGTAGATG-3′) PCR primers. To 
determine indels and DNA sequences of knockout clones, 
the PCR-products were first purified by QIAQuick PCR 
purification before direct Sanger sequencing followed 
by TIDE and “mixed sequence reader” analysis [74, 75]. 
To this end, the uPARAP knockout (-/-) monoclone 2A3 
used herein, was determined to contain a targeted 1 nt 
insertion (A) and a 4 nt deletion (TTCA), respectively, in 
the uPARAP-encoding alleles.
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Cell lines were maintained in the following media: 
unmodified U937, U937 clone 2A3, THP-1 and NB-4 
in RPMI; HT1080, RD, U373, HS683 and HEK293 in 
DMEM; KNS42 in DMEM/F-12, and GCT in McCoy’s 
5A medium. All media were supplemented with 10% fetal 
bovine serum and 1% penicillin/streptomycin, and cells 
were maintained in a 37°C, 5% CO2 atmosphere incubator.
Western blot for detection of uPARAP expression 
in cell lysates
For preparation of cell lysates, cells were treated 
on ice for 20 min with lysis buffer (10 mM Tris, 140 
mM NaCl, 1% Triton X-100, pH 7.4, including protease 
inhibitor cocktail set III EDTA-free (Calbiochem) diluted 
1:200), using 100µL of lysis buffer per 1x106 cells, then 
centrifuged at 20,000 x G. Sample protein content was 
measured by Pierce BCA analysis (ThermoFisher). 25 
µg of total protein per sample was then run on a 4-12% 
gradient gel using the NuPAGE Bis-Tris SDS-PAGE gel 
and reagent system (ThermoFisher Scientific). Using 
an iBlot transfer system (Invitrogen), gel contents were 
transferred to a PVDF membrane using a Novex PVDF 
gel transfer stack (Invitrogen). The membrane was then 
blocked in 2% BSA in PBS pH 7.4 for 30 minutes.
Membranes were then incubated in primary antibody 
(anti-uPARAP mAb 2h9 at 0.5 µg/mL or anti-human 
GAPDH mAb #VMA00046 from Bio-Rad (loading 
control) 1:2000), diluted in PBS with 0.1% Tween 20, pH 
7.4, followed by HRP-conjugated secondary rabbit anti-
mouse antibody 1:6000 (#P0260, Dako Denmark), and 
treatment for 5 minutes with Amersham ECL Western 
Blotting Detection Reagent (#RPN2106, GE Healthcare), 
with intermediate washing steps. The blot was developed 
by a brief exposure onto Amersham Hyperfilm ECL 
(#28906837, GE Healthcare).
In these analyses, the THP-1 cell line displayed a 
reduced GAPDH signal, although identical amounts of 
total protein were analyzed and loaded as measured by 
Pierce BCA analysis (Figure 1A). A parallel gel stained 
with Coomassie Blue confirmed a uniform protein loading 
for all cell lines analyzed (Supplementary Figure 2).
Analysis of cellular uptake of fluorescence 
labeled mAb against uPARAP
Fluorescently labeled antibodies 2h9 and aTNP were 
prepared by subjecting the antibodies to a mild reduction 
with 10 mM DTT in PBS, pH 7.4 for 30 minutes at 37°C, 
followed by buffer exchange to fresh PBS pH 7.4 using a 
30 kDa NMWL Amicon Ultra Centrifugal Filters (Merck 
Millipore). Antibodies at 2 mg/mL were then allowed to 
react with a 5-fold molar excess of Alexa Fluor 647 C2 
Maleimide (AF647, Thermo Fischer Scientific) for 2 hours 
at room temperature, and then purified by gel filtration on 
PD-10 desalting columns (GE Healthcare Life Sciences).
For analysis of cellular uptake of antibodies, cells 
were incubated for 4 hours with AF647-labeled mAbs at 5 
µg/mL. A nuclear Hoechst stain (#62249, Thermo Fisher) 
was added at 2 µg/mL in cell medium for 20 minutes 
before washing, followed by treatment with a mixture of 
0.25% trypsin-EDTA (Gibco, Life Technologies) and 50 
µg/mL proteinase K (Roche) in order to remove surface-
bound antibodies. For staining of the plasma membrane, 
an anti-human CD45 mAb (#368502, BioLegend) was 
fluorescence-labeled using a Zenon Alexa Fluor 488 
Mouse IgG1 Labeling Kit (#Z25002, Thermo Fisher 
Scientific), then added to the cells at 5 µg/mL in PBS for 
20 minutes. Cells were then spun down onto a microscope 
glass slide (Superfrost ultra plus, Thermo Scientific) 
using a Hettich cyto-system at 500xG for 1 minute in 4 
mL one-funnel chambers (#M966-4, Simport, Canada), 
and mounted in ProLong Gold (Thermo Fisher Scientific) 
under a cover slide. Samples were then examined using a 
Leica TCS SP8 confocal laser microscope.
Preparation and characterization of mAb-vc-
MMAE ADCs
For preparation of ADCs, antibodies were subjected 
to mild reduction by a 15 minute incubation at 37°C in the 
presence of 10 mM DTT in a 50 mM sodium borate, 50 mM 
NaCl, pH 8.0 buffer at an IgG concentration of 5 mg/mL, 
followed by buffer exchange to fresh PBS pH 7.4 with 1 mM 
EDTA, using 30 kDa Ultra Centrifugal Filters as described 
above. This was followed by immediate conjugation by 
addition of a molar excess of maleimidocaproyl-valine-
citrulline-p-aminobenzoyloxycarbonyl-monomethyl 
auristatin E (MC-VC-PAB-MMAE, Levena Biosystems, 
San Diego, USA), dissolved in water-free DMSO to a final 
DMSO content of 10% v/v during conjugation for 2 hours 
at 37°C. Amounts of MC-VC-PAB-MMAE were adjusted 
according to the desired DAR; see below. The resulting 
mAb-vc-MMAE ADCs were purified by gel filtration on 
PD-10 desalting columns (GE Healthcare Life Sciences). 
The average DAR of the resulting ADCs was measured 
based on the absorbance ratios of purified conjugate 
preparations at λ=248nm (A
max
 of MMAE) and λ=280nm, 
respectively, using previously determined reference values 
[43, 76]. With the coupling method employed, conjugation 
of MC-VC-PAB-MMAE at 5-fold molar excess over mAb 
resulted in moderate DARs of 4-5, whereas conjugation at 
10-fold molar excess resulted in a DAR of about 10. For 
cytotoxicity studies in vitro, ADCs with a DAR~10 were 
employed. Studies in vivo were performed using ADCs with 
a DAR of 4-5.
Electrophoretic analysis of conjugate species and 
test of linker cleavage
SDS-PAGE was performed with 5 µg of total 
protein per lane, using the same gel system as described 
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above for Western blotting. Samples were reduced by 
boiling for 3 minutes in sample buffer in the presence 
of 40 mM DTT before electrophoresis. A protein marker 
was run in separate lanes for Mr determination. Gels 
were stained using a standard 0.1% Coomassie blue stain. 
For linker cleavage assays, samples of mAb-vc-MMAE 
were treated with recombinant human (rh) Cathepsin B 
(#953-CY, R&D systems) according to the manufacturer’s 
instructions, using 100 ng of activated rhCathepsin B 
to 20 µg mAb or ADC (mAb component) in a 25 mM 
2-(N-morpholino) ethanesulfonic acid (MES) buffer, pH 
5.0, and incubation at 37°C overnight.
ELISA of uPARAP-binding by conjugated mAbs
A 96-well ELISA plate was coated with 25 ng/well 
of a soluble truncated uPARAP protein comprising the first 
3 domains of uPARAP, containing the epitope for mAb 
2h9 [29, 30]. Dilution series of untreated mAbs (2h9 or 
aTNP), partially reduced mAbs (see above), or ADCs 2h9-
vc-MMAE or aTNP-vc-MMAE, were then employed as 
the primary antibody in an ELISA setup, followed by an 
HRP-conjugated rabbit anti-mouse Ig secondary antibody 
(Dako Denmark). Finally, an o-phenylenediamine 
dihydrochloride (OPD) ELISA substrate solution (Dako) 
was added, and the color reaction was stopped by adding 
1M H2SO4. Plates were read at 492 nm using a plate 
reader.
Cytotoxicity of 2h9-vc-MMAE in vitro - cell 
viability assay and cell cycle analysis
For cell viability assays, cells were seeded at low 
density, generally 1x103 to 2.5x103 cells per well, in a 
flat-bottomed 96-well cell culture plate (Costar) in 90 µL 
of cell culture medium. The next day, mAb-vc-MMAE 
conjugates were prepared as a serial dilution (1:4) in 
PBS and added in volumes of 10 µL to each well, with 
a maximum final ADC concentration of 10 µg/mL mAb 
component in cell culture medium with 10% v/v PBS. 
Cells were incubated for 72 hours before evaluating 
overall viability by adding 12 µL of CellTiter 96 AQueous 
One Solution Cell Proliferation Assay (MTS) (Promega), 
and then further incubating for an appropriate time for 
formation of color (15-60 mins). The plates were then 
read at 490 nm, with background subtraction at 630 nm 
using a plate reader, and viability calculated as percentage 
of an internal plate control of untreated cells. For cell 
cycle analyses, cells were seeded and treated with 2h9-vc-
MMAE as above, at a concentration yielding about 50% 
viability in the abovementioned MTS viability assays. 
After 3 days, cell cycle analysis was performed using a 
Nucleocounter NC-3000 system (ChemoMetec Denmark), 
according to the manufacturer’s standard protocol for 
analyzing the cell cycle distribution in a population of 
cells, based on DNA content. The percentage of cells in 
Sub-G1-, G1-, S-, or G2/M-phases of the cell cycle was 
established from histogram analysis using the NucleoView 
NC-3000 software.
Receptor competition assay, receptor depletion 
assay and lysosomal protease inhibition
These experiments were done in the form of cell 
viability assays with U937 cells, performed as above, 
except that additional reagents were added, either in 
a pre-treatment step or at the start of ADC treatment of 
cells. Receptor competition assay was performed with 
a constant 2h9-vc-MMAE concentration of 1 µg/mL 
mAb component in all wells, and with the ADC and the 
unmodified competing mAb being added simultaneously. 
Competing mAbs were used in dilution series (1:2), 
starting at 8 µg/mL and were present throughout the assay. 
For receptor depletion assay, cells were pre-incubated in 
the presence of mAb 5f4 at 10 µg/mL for 3 hours, before 
starting a 72 hour cell viability assay in the presence of 
2h9-vc-MMAE as described above. For the inhibition of 
lysosomal proteases, U937 cells were pre-incubated with 
20 µM of E-64D protease inhibitor (Sigma-Aldrich) for 2 
hours, before starting a 72 hour cell viability assay in the 
same manner.
Animal experiments
All animal experiments were performed 
under legal approval from The Danish Veterinary 
and Food Administration, under license number 
2014−15−0201−00322 (L. H. Engelholm). All reagents 
and cell lines used for animal experiments were tested 
negative for the presence of endotoxins, murine viruses, 
bacteria, mycoplasma and fungi (Taconic Europe, Ry, 
Denmark). For all studies, animals received standard of 
care, according to Danish animal welfare legislation.
A xenograft model with subcutaneous inoculation 
of human U937 cells was established in CB17 SCID 
mice (Janvier Labs). Mice were injected subcutaneously 
in the upper right flank with 1x106 U937 cells in 100 µL 
PBS, resulting in the formation of tumors displaying rapid 
growth, with an observed doubling in tumor volume of 
approximately 3-4 days. Tumor growth was followed 
by palpation using electronic calipers. Volumes were 
calculated using the formula V=(LxW2)/2, with L being 
the longest dimension of the tumor and W being the 
corresponding tumor width.
Studies on treatment of subcutaneous tumors were 
performed with either local (subcutaneous) or systemic 
(intravenous) administration of reagents. For the study on 
local administration, upon formation of palpable tumors 
with a volume of ~50-100 mm3, mice were randomized 
into four treatment groups, receiving either 2h9-vc-MMAE 
(N=10), aTNP-vc-MMAE (N=9; one mouse in a group of 
10 failed to develop palpable tumors), unmodified mAb 
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2h9 (N=5) or PBS vehicle control (N=5). All treatments 
were given as a total of four subcutaneous doses of 3 mg/kg 
mAb component near the tumor, with one dose every four 
days (q4dx4 schedule). Injections were performed under 
brief isoflurane anesthesia. During treatment, the tumors 
were measured every second day, until reaching a point 
of sacrifice (euthanasia due to tumor burden). Mice which 
completely lost any tumor burden were then examined twice 
a week for a period of 3 months after the final injection.
For the study on systemic treatment, mice were 
inoculated with U937 cells as above, again allowing 
tumors to reach a volume of ~50-100 mm3 before initiation 
of treatment. The four treatment groups received either 
2h9-vc-MMAE (N=10), aTNP-vc-MMAE (N=10), 
unmodified mAb 2h9 (N=5) or PBS vehicle control (N=5). 
All treatments were given as a total of three intravenous 
doses of 5 mg/kg mAb component in the tail vein, every 
four days (q4dx3 schedule). During treatment, tumors 
were measured every second day, until reaching a point 
of sacrifice (euthanasia due to tumor burden). Mice which 
completely lost any tumor burden were examined twice 
a week for a period of 3 months after the final injection.
Treatment experiments were performed with the 
researcher responsible for injecting mice and evaluating 
tumor size being blinded from the identity of the treatment 
groups.
Harvest and processing of tissue for 
immunohistochemical staining
Tumor tissue was harvested from tumor-bearing mice 
upon reaching a point of sacrifice: Mice received anesthesia 
(Hypnorm/Midazolam), and the mice were perfused by 
intracardial injection of 10 mL PBS. The tumors were then 
surgically removed and cut in half, with one half being 
immediately frozen in a mixture of dry ice and ethanol for 
Western blot analysis of uPARAP expression, and one half 
being transferred to a 4% PFA solution for histological 
processing. Bones were dissected and transferred to a 4% 
PFA solution in a similar manner. After 24 hours of incubation 
at 4°C, tissue samples for histology were transferred to 70% 
ethanol. Bones were decalcified in a 10% water solution of 
EDTA, adjusted to pH 7.4, by microwave heating steadily 
to 50°C for 20 minutes at 600W, then maintaining 50°C for 
2 hours at 300W. To ensure complete decalcification, the 
femurs were stored in fresh 10% EDTA, pH 7.4, for 3 days at 
4°C. Samples for histology were then dehydrated with 70%, 
96% and 99% ethanol, followed by xylene, and subsequently 
embedded in paraffin. The embedded tissue samples 
were sectioned at 3-3.5 µm on an automatic microtome 
(#HM355S, Thermo Scientific), and mounted on glass slides.
Immunohistochemical staining of tissue samples
uPARAP and hCD45 staining: Samples were 
deparaffinized and subjected to a pretreatment with 
proteinase K at 5 µg/mL (uPARAP) or 10 mM citrate 
buffer, pH 6.0 (hCD45), as well as blocking of 
endogenous peroxidase by 1% H2O2, before incubation 
with primary detection antibody (anti-uPARAP: rabbit-
anti-human pAb [2] at 0.5 µg/mL, anti-hCD45: #368502, 
Biolegend, at 1 µg/mL) overnight at 4°C. Envision-
HRP anti-rabbit (#4003, Dako) or Envision-HRP anti-
mouse (#K4001, Dako) was employed as a secondary 
antibody, respectively, and NovaRED HRP substrate 
(#SK-4800, Vector Burlingame) was added as a color 
substrate for 9 minutes before rinsing and adding a 
hematoxylin counterstain (HARRIS HTX solution, 
#01800, HistoLab). Samples were finally dehydrated 
with increasing concentrations (70%, 96% and 99%) of 
ethanol, followed by xylene, and mounted with Pertex 
(#20080, Sakura Finetek). H&E staining: Samples were 
deparaffinized, rinsed in water, and subjected to a staining 
with hematoxylin (HARRIS HTX solution, #01800, 
HistoLab) for 5 minutes followed by staining with eosin 
(eosin solution 0.2%, #8702, Sakura Finetek) for 5 
minutes. Samples were finally dehydrated with increasing 
concentrations of ethanol followed by xylene and mounted 
with Pertex, all being performed as above. Apoptosis 
staining: Staining for apoptotic cells was performed using 
the In situ Apoptosis Detection Kit (#ab206386, Abcam), 
according to the enclosed manual. Briefly, samples 
were first deparaffinized and subjected to a pretreatment 
with proteinase K, as well as blocking of endogenous 
peroxidase by 3% H2O2. Biotin-labeling of exposed 3′-OH 
ends of DNA of apoptotic cell nuclei was then performed 
by adding TdT enzyme and TdT labeling reaction mix for 
90 minutes at room temperature, after which the reaction 
was stopped using the stop buffer. Biotinylated DNA was 
detected by incubation with a streptavidin-HRP conjugate 
for 30 minutes at room temperature, followed by a 
diaminobenzidine (DAB) substrate solution for 15 minutes 
at room temperature. The samples were counterstained 
with methyl green, dehydrated and mounted as above. Ki-
67 staining: Samples were deparaffinized and subjected 
to a pretreatment with 10 mM citrate buffer, pH 6.0 at 
98°C for 10 minutes, as well as blocking of endogenous 
peroxidase by 1% H2O2, before incubation with primary 
detection antibody (rabbit-anti-Ki67 mAb, #ab16667, 
Abcam, 1:100) overnight at 4°C. Envision-HRP anti-rabbit 
(#4003, Dako) was employed as a secondary antibody, and 
NovaRED HRP substrate (#SK-4800, Vector Burlingame) 
was added as a color substrate for 9 minutes before rinsing 
and adding a hematoxylin counterstain (HARRIS HTX 
solution, #01800, HistoLab). Dehydration and mounting 
of samples were then performed as described above.
Western blot of tumor samples for uPARAP 
expression
Tumor samples were crushed to a fine powder 
in liquid nitrogen, transferred to Eppendorf tubes, and 
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dissolved in lysis buffer (0.1 M Tris, 50 mM NaCl, 1% 
CHAPS, pH 7.5, including protease inhibitor cocktail III 
1:200 (VWR)), using 800 µL of lysis buffer per 150 mg 
tissue. The tissue was lysed using a chilled polytron tissue 
homogenizer for 2x20 seconds, or until homogenous 
appearance. Samples were centrifuged at 12,000 x G at 4°C, 
and the supernatant transferred to fresh tubes. The protein 
content was determined by BCA analysis as above. Tissue 
lysate samples of 20µg total protein per lane were separated 
by SDS-PAGE and transferred to a PVDF membrane, as 
described above. For specific detection of uPARAP, mAb 
2h9 was labeled with 125I [77]. The membrane was then 
blocked in 2% BSA, and incubated overnight at 4°C with 20 
ng/mL of the radiolabeled detection antibody, before being 
washed in PBS pH 7.4 and water. Using a Fuji FLA-3000 
system, an imaging plate was then exposed to the membrane 
overnight, and developed the following day.
Statistics
ELISA data are represented as mean of duplicates. 
All other data are represented as mean ± standard 
deviation of triplicates. Statistical analysis was performed 
as a standard t-test.
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